Cedarbenemide efficacy is mainly anti-tumor, the specific use of medication as prescribed by the doctor.
Cedarbenazine is a selective inhibitor of the histone deacetylase subtype of benzamide, which can inhibit the tumor cell cycle, induce apoptosis of tumor cells, induce the body’s immune cells to produce tumor killing effect, but also can induce tumor stem cell differentiation, reverse the epithelial-mesenchymal phenotypic transformation of the tumor cells, etc. The drug is suitable for use in relapsed or refractory peripheral T-cell lymphoma that has received at least one previous systemic chemotherapy.
The drug is suitable for use in relapsed or refractory peripheral T-cell lymphoma having received at least one prior systemic chemotherapy. It needs to be contraindicated in patients who are allergic to cedarbenazine or any of its components, female patients during pregnancy, and patients with severe cardiac insufficiency.
Common adverse reactions include decreased platelet count, decreased white blood cell or neutrophil count, decreased hemoglobin, malaise, fever, diarrhea, nausea, vomiting, decreased appetite, hypokalemia, hypocalcemia, dizziness, and skin rash. Specific medication should be administered under the guidance of a specialist.